Shares of Sol-Gel Technologies Ltd. SLGL, +89.60% gained 154% in premarket trading on Monday after the Israeli drugmaker said its acne drug Twyneo met the primary endpoints in two late-stage trials. The topical treatment is a combination of benzoyl peroxide and tretinoin. Sol-Gel plans to submit a new drug application for Twyneo to the Food and Drug Administration in the second half of 2020. It is also developing a treatment for rosacea. In early December Raymond James analyst Elliot Wilbur wrote “we continue to have confidence in the potential for both branded products, Twyneo (acne vulgaris) and Epsolay (papulopustular rosacea), to emerge as best-in-class therapies.” Sol-Gel’s stock is up 53% year-to-date, while the S&P 500 SPX, -0.66% has gained 29%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.